Equities analysts forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will post earnings of ($0.75) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Dicerna Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($0.81). Dicerna Pharmaceuticals posted earnings per share of ($0.68) during the same quarter last year, which indicates a negative year over year growth rate of 10.3%. The firm is expected to announce its next earnings results on Monday, November 6th.

Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.54. The firm had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. The business’s revenue for the quarter was up 2400.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.75) EPS.

DRNA has been the topic of a number of research analyst reports. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 9th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 23rd. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 22nd. Finally, Chardan Capital reiterated a “hold” rating on shares of Dicerna Pharmaceuticals in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Dicerna Pharmaceuticals presently has an average rating of “Hold” and an average target price of $6.35.

Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up 1.2382% during trading on Monday, reaching $3.2295. 5,377 shares of the company’s stock traded hands. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $6.10. The stock’s market capitalization is $67.32 million. The stock has a 50-day moving average price of $3.42 and a 200 day moving average price of $3.14.

Several institutional investors have recently added to or reduced their stakes in DRNA. EcoR1 Capital LLC boosted its position in Dicerna Pharmaceuticals by 101.0% in the second quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock valued at $2,435,000 after buying an additional 385,992 shares in the last quarter. Palo Alto Investors LLC boosted its position in Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after buying an additional 19,394 shares in the last quarter. Vanguard Group Inc. boosted its position in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after buying an additional 14,517 shares in the last quarter. Northern Trust Corp boosted its position in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 2,094 shares in the last quarter. Finally, Bourgeon Capital Management LLC boosted its position in Dicerna Pharmaceuticals by 188.9% in the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 25,500 shares in the last quarter. 55.54% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “-$0.75 EPS Expected for Dicerna Pharmaceuticals, Inc. (DRNA) This Quarter” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2017/08/28/0-75-eps-expected-for-dicerna-pharmaceuticals-inc-drna-this-quarter.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.